BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 19125003)

  • 1. New therapeutic agents in ovarian cancer.
    Collinson F; Jayson G
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):44-53. PubMed ID: 19125003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted agents in ovarian cancer.
    Kristedja TS; Morgan RJ; Cristea M
    Womens Health (Lond); 2010 Sep; 6(5):679-94. PubMed ID: 20887168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S
    BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drugs for ovarian cancer.
    Kaye SB
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):91-3. PubMed ID: 18347558
    [No Abstract]   [Full Text] [Related]  

  • 5. Angiogenesis inhibitors for the treatment of ovarian cancer.
    Gaitskell K; Martinek I; Bryant A; Kehoe S; Nicum S; Morrison J
    Cochrane Database Syst Rev; 2011 Sep; (9):CD007930. PubMed ID: 21901715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab in the treatment of ovarian cancer.
    Han ES; Monk BJ
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis as a strategic target for ovarian cancer therapy.
    Spannuth WA; Sood AK; Coleman RL
    Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis as a target for the treatment of ovarian cancer.
    Shaw D; Clamp A; Jayson GC
    Curr Opin Oncol; 2013 Sep; 25(5):558-65. PubMed ID: 23942301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic drugs in ovarian cancer.
    Kumaran GC; Jayson GC; Clamp AR
    Br J Cancer; 2009 Jan; 100(1):1-7. PubMed ID: 19002176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status on biologic therapies in the treatment of epithelial ovarian cancer.
    Han ES; Lin P; Wakabayashi M
    Curr Treat Options Oncol; 2009 Apr; 10(1-2):54-66. PubMed ID: 19381822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line chemotherapy in epithelial ovarian cancer.
    Bookman MA
    Clin Obstet Gynecol; 2012 Mar; 55(1):96-113. PubMed ID: 22343232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug insight: VEGF as a therapeutic target for breast cancer.
    Schneider BP; Sledge GW
    Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New ways to successfully target tumor vasculature in ovarian cancer.
    Yang X; Shen F; Hu W; Coleman RL; Sood AK
    Curr Opin Obstet Gynecol; 2015 Feb; 27(1):58-65. PubMed ID: 25502429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
    Al Wadi K; Ghatage P
    Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular/genetic therapies in ovarian cancer: future opportunities and challenges.
    Ziebarth AJ; Landen CN; Alvarez RD
    Clin Obstet Gynecol; 2012 Mar; 55(1):156-72. PubMed ID: 22343235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New biological treatments for lung cancer].
    Zalcman G; Richard N; Bergot E
    Rev Pneumol Clin; 2007 Feb; 63(1):20-8. PubMed ID: 17457280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel antiangiogenic therapies in ovarian cancer.
    Stuckey A; Dizon DS
    Womens Health (Lond); 2012 Jul; 8(4):447-53. PubMed ID: 22757735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
    Asmane I; Kurtz JE; Bajard A; Guastalla JP; Meeus P; Tredan O; Labidi Galy I; Moullet I; Ardisson P; Vincent L; Coeffic D; Dufresne A; Bergerat JP; Ray-Coquard I
    Bull Cancer; 2011 Oct; 98(9):80-9. PubMed ID: 21926034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.